GH Research (FRA:1KA) Days Payable: 0.00 (As of Mar. 2026)

What is GH Research Days Payable?

GH Research FRA:1KA +14.68% 36 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates FRA:1KA with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 705 Biotechnology companies, GH Research ranks worse than 141843.83% on this metric.

GH Research's average Accounts Payable for the three months ended in Mar. 2026 was €3.87 Mil. GH Research's Cost of Goods Sold for the three months ended in Mar. 2026 was €0.00 Mil.

The historical rank and industry rank for GH Research's Days Payable or its related term are showing as below:

FRA:1KA's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.36
* Ranked among companies with meaningful Days Payable only.

GH Research's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

GH Research Days Payable Related Terms

GH Research Days Payable Historical Data

* Premium members only.

The historical data trend for GH Research's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GH Research Days Payable Chart

GH Research Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Days Payable

Get a 7-Day Free Trial

0.00

GH Research Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

FRA:1KA vs ATAI, RAPP, NUVB: Days Payable Comparison

For the Biotechnology subindustry, GH Research's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GH Research Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GH Research's Days Payable distribution charts can be found below:

* The bar in red indicates where GH Research's Days Payable falls into.

Save Embed

36GF Score

GH Research PLC FRA:1KA

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

GH Research Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

GH Research's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

	Days Payable (A: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2024 )	+	Accounts Payable (A: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2025 )	*	Days in Period
=	( (3.573	+	3.222)	/	2 )	/	0	*	365
=	3.3975					/	0	*	365
=	N/A

GH Research's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (3.222	+	4.508)	/	2 )	/	0	*	365 / 4
=	3.865					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

GH Research (FRA:1KA) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GH Research and its competitors. According to the industry distribution chart, GH Research ranks #999999 out of 705 companies in the Biotechnology industry.

Is GH Research's Days Payable too high?

GH Research's current Days Payable is 0.00. Based on the distribution chart, GH Research ranks #999999 out of 705 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GH Research has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.

How does GH Research's Days Payable compare to ATAI and RAPP?

According to the Biotechnology industry distribution chart, GH Research ranks #999999 out of 705 companies for Days Payable. This places GH Research in the lower half of its industry. The industry median Days Payable is 113.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GH Research and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GH Research's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is GH Research stock overvalued right now?

GH Research (FRA:1KA) has a current Days Payable of 0.00. The current Days Payable is 0.00. GH Research's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For GH Research (FRA:1KA), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GH Research Business Description

Industry Healthcare Biotechnology

Comparable Companies ATAI RAPP NUVB SION VRDN TYRA IOVA SNDX STOK GLUE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges GHRS:USA

Address Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95

Website https://www.ghres.com

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

36GF Score

Get the complete analysis for FRA:1KA

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€25.00

Price

View FRA:1KA Analysis

See Days Payable data for all stocks →